Wyeth Protonix I.V. "Coming Soon" Promotions Challenged By FDA
Executive Summary
FDA is challenging Wyeth-Ayerst's "Coming Soon" promotions for Protonix I.V. on the grounds that they failed to disclose "facts that are material" to the status of the intravenous proton pump inhibitor.
You may also be interested in...
Wyeth Protonix I.V. Indicated As Second-Line Therapy After Oral Pantoprazole
Wyeth-Ayerst's intravenous proton pump inhibitor Protonix will be launched in mid-April as a second-line alternative to Protonix (pantoprazole) tablets.
Wyeth Protonix I.V. Indicated As Second-Line Therapy After Oral Pantoprazole
Wyeth-Ayerst's intravenous proton pump inhibitor Protonix will be launched in mid-April as a second-line alternative to Protonix (pantoprazole) tablets.
FDA Off-Label Notice Stands, But Enforcement Still Vulnerable - Judge
FDA remains vulnerable to future First Amendment challenges if it uses off-label reprints as evidence on misbranding cases, Judge Royce Lamberth suggested in a Nov. 30 court order.